Tuesday - May 13, 2025
PURCHASE, N.Y., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today announced that it issued inducement awards to two new employees.
Effective October 1, 2023 and October 2, 2023, in connection with commencing employment, two new non-executive employees of Teladoc Health were granted options to purchase an aggregate of 64,616 shares of Teladoc Health’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price per share of $18.59 and $18.43, respectively, and awards of restricted stock units covering an aggregate of 36,508 shares of Common Stock. The stock options vest, based on continued service to Teladoc Health, as to twenty-five percent of the underlying shares on October 1, 2024, with the remainder of the option vesting monthly over three years thereafter. The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on October 1, 2024, with the remainder vesting quarterly over two years thereafter. The awards were approved by the Compensation Committee of the Board of Directors of Teladoc Health and were granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as employment inducement awards pursuant to New York Stock Exchange Rule 303A.08.
About Teladoc Health
Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com
Media:
Chris Stenrud
860-491-8821
pr@teladochealth.com
Last Trade: | US$7.35 |
Daily Change: | 0.24 3.38 |
Daily Volume: | 4,402,291 |
Market Cap: | US$1.270B |
April 30, 2025 April 30, 2025 March 12, 2025 March 11, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load